SCHEMBL6894147

SCHEMBL6894147

COC(=O)CCCc1cc(N)n2ncc(-c3cnc4ccccc4c3)c2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 4/20 0.42
KMT2A Q03164 3/20 0.40
KDM4E B2RXH2 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
GFER P55789 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MTOR P42345 4/20 0.38
AKT1 P31749 2/20 0.38
HSP90AA1 P07900 1/20 0.38
HDAC1 Q13547 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6894157 0.96 PIK3CA (0.41) PIK3CAKMT2AKDM4ESMN1; SMN2MEN1
SCHEMBL7878815 0.89 PIK3CA (0.44) PIK3CAKMT2AKDM4ESMN1; SMN2MEN1
SCHEMBL2679636 0.85 PIK3CA (0.43) PIK3CAKMT2AKDM4ESMN1; SMN2MEN1
SCHEMBL10239378 0.84 LTB4R (0.37) KMT2AKDM4ESMN1; SMN2MEN1MAPT
SCHEMBL6894012 0.79 PIK3CA (0.44) PIK3CAKMT2AKDM4ESMN1; SMN2MEN1
SCHEMBL7874886 0.78 LTB4R (0.34) KMT2AMEN1MAPTMTORHDAC1
SCHEMBL6893473 0.76 KDM4E (0.42) PIK3CAKMT2AKDM4ESMN1; SMN2MEN1
SCHEMBL6893413 0.75 MAPT (0.44) PIK3CAKMT2AKDM4ESMN1; SMN2MEN1
SCHEMBL6893465 0.75 PIK3CA (0.39) PIK3CAKMT2AKDM4ESMN1; SMN2MEN1
SCHEMBL7880714 0.75 KDM4E (0.41) PIK3CAKMT2AKDM4ESMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 PIK3CA 2681/4885KMT2A 3565/4885KDM4E 3091/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR PIK3CA 34/4885KMT2A 2825/4885KDM4E 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.